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IMPORTANCE Sociocommunicational deficits make it difficult for individuals with autism
spectrum disorders (ASD) to understand communication content with conflicting verbal and
nonverbal information. Despite growing prospects for oxytocin as a therapeutic agent for
ASD, no direct neurobiological evidence exists for oxytocin’s beneficial effects on this core
symptom of ASD. This is slowing clinical application of the neuropeptide.
OBJECTIVE To directly examine whether oxytocin has beneficial effects on the
sociocommunicational deficits of ASD using both behavioral and neural measures.
DESIGN, SETTING, AND PARTICIPANTS At the University of Tokyo Hospital, we conducted a
randomized, double-blind, placebo-controlled, within-subject–crossover, single-site
experimental trial in which intranasal oxytocin and placebo were administered. A total of 40
highly functioningmenwith ASD participated and were randomized in the trial.
INTERVENTIONS Single-dose intranasal administration of oxytocin (24 IU) and placebo.
MAIN OUTCOMES ANDMEASURES Using functional magnetic resonance imaging, we
examined effects of oxytocin on behavioral neural responses of the participants to a social
psychological task. In our previous case-control study using the same psychological task,
whenmaking decisions about social information with conflicting verbal and nonverbal
contents, participants with ASDmade judgments based on nonverbal contents less
frequently with longer time and could not induce enough activation in themedial prefrontal
cortex. Therefore, our main outcomes andmeasures were the frequency of the nonverbal
information–based judgments (NVJs), the response time for NVJs, and brain activity of the
medial prefrontal cortex during NVJs.
RESULTS Intranasal oxytocin enabled the participants to make NVJs more frequently (P = .03)
with shorter response time (P = .02). During themitigated behavior, oxytocin increased the
originally diminished brain activity in themedial prefrontal cortex (P < .001). Moreover,
oxytocin enhanced functional coordination in the area (P < .001), and themagnitude of these
neural effects was predictive of the behavioral effects (P  .01).
CONCLUSIONS AND RELEVANCE These findings provide the first neurobiological evidence for
oxytocin’s beneficial effects on sociocommunicational deficits of ASD and give us the initial
account for neurobiological mechanisms underlying any beneficial effects of the
neuropeptide.
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A utism spectrum disorders (ASD) affect approximately1%of thegeneral population,1 andcurrently there isnoestablished pharmacological treatment for their core
symptoms.Thedisordershave 3 core symptoms: impaired so-
cial interaction, impairments in communication, and repeti-
tive and restricted behavior.2,3 As indicated through revision
of the definition of the disorder (DSM-5, http://www.dsm5
.org/), sociocommunicational deficits derived from the inte-
gration of the former 2 core symptomsmake it difficult for in-
dividualswithASDtounderstandthecontentofcomplexsocial
communications, suchas ironyandhumor, thathave conflict-
ing nonverbal and verbal information.4-11 Because of this dif-
ficulty, individuals with ASD, even those with high intelli-
gence, often fail to properly understand others’ intentions in
their daily communications.
Recently, a seriesof studies raised thepossibility that some
ASD symptoms may be relieved by administration of
oxytocin,3,12,13 a neuropeptide known to play a key role in so-
cial andaffiliativebehavior.12-21 Prior studieswith typicallyde-
veloped (TD) individuals have shown that oxytocin modu-
lates their neural responses to social stimuli, enhances social
perception, and promotes social interactions with modula-
tionof functional connectivity.14,15,18,22,23 Although there is no
neurobiological evidence for the effects of oxytocin on indi-
vidualswithASDand fewstudieshave includedoxytocin’s ef-
fect as amaineffect in their analyses, previouspreliminarybe-
havioral studies in individualswithASD in small sample sizes
(N < 20) have supported oxytocin’s potential as a therapy for
some of the core symptoms of ASD. Restricted and repetitive
behaviors were significantly reduced by oxytocin infusion.24
Social interactionsandsocial recognitionweresignificantlyen-
hanced by intranasal administration of oxytocin to individu-
alswith ASDwhen the social interactionsmostly consisted of
nonverbal information, such as facial expressions and eye
gazes.25-28
However, to our knowledge, no previous study has di-
rectly demonstrated that oxytocin improves sociocommuni-
cationaldeficitsofASD insimultaneousprocessingofbothver-
balandnonverbal information.This lackof study is likelypartly
attributable to the difficulty in designing a psychological task
that is sensitive to thedeficits,which are occasionallymasked
by the preserved intelligence of highly functioning individu-
als with ASD.4,25-27,29We devised a psychological task that re-
quires participants to make judgments regarding the inten-
tions of others based on sociocommunicational content in
which theverbalandnonverbal informationconflicts.This task
is thought to be appropriate for examining oxytocin’s effects
on sociocommunicational deficits ofASDbecause, in our pre-
vious case-control study using functional magnetic reso-
nance imaging (fMRI),8 thesametaskenabledus todetectASD-
specific neural responses whose magnitudes significantly
correlated with the severity of sociocommunicational defi-
cits.Moreover, previous studies have also suggested that psy-
chological tasks focusing on understanding others’ inten-
tion, basedonaprocess of verbal andnonverbal conflicts, can
effectively detect sociocommunicational deficits in individu-
als with ASD.4,6,7,9-11 Furthermore, previous studies have also
demonstrated oxytocin’s effects on perception and interpre-
tationofnonverbal social information including facial expres-
sion and emotional prosody.25-28,30,31 Considering these pre-
vious findings, it is reasonable to assume that observation of
behavioral andneural activity during the judgment of others’
intention, based on the verbal and nonverbal conflicting in-
formation,mayallowdetectionof oxytocin’s effects on socio-
communicational deficits in individuals with ASD.
In the present task, participants are presentedwith short
movies inwhichprofessional actors speak an emotionalword
(verbal information) with an emotional facial expression and
expressivevoiceprosody (nonverbal information) (Figure 1A).
Themovies consist of 2 types of emotionally congruentmov-
ies with negative (NV−V−) or positive (NV+V+) nonverbal and
verbal information and 2 types of incongruent movies with
negativenonverbalandpositiveverbal (NV−V+)orpositivenon-
verbal and negative verbal (NV+V−) information (eFigure 1 in
Supplement). On the basis of the integration of the verbal and
nonverbal information, participants are instructed to make a
“friendor foe” judgmentof theactor ineachmovie (Figure 1B).
According to the type of information with the strongest ef-
fects on the judgments, the responses to the incongruent
stimuliwereclassified intononverbal information–based judg-
ments (NVJs) and verbal information–based judgments (VJs).
For example, a judgmentof foe in response toanNV−V+stimu-
luswas regarded as anNVJ, and a judgment of foe in response
toanNV+V−stimuluswas regardedasaVJ (Figure 1B). It should
benoted that this psychological taskdoesnot focuson thedif-
ference in cognitiveprocesses betweena friend judgment and
a foe judgment but instead focuses on the difference be-
tween NVJs and VJs.
Inourpreviouscase-control fMRI study that comparedbe-
havioral andneural responses during the task betweenTD in-
dividuals and those with ASD,8 the individuals with ASD
showed significantly fewer NVJs with significantly longer re-
sponse times (eFigure 2 in Supplement). During the judg-
ments, they also showed significantly diminishedbrain activ-
ity in several brain regions, includingmedialprefrontal regions
(eTable 2 in Supplement).
In this double-blind, placebo-controlled,within-subject–
crossover trial for single-dose intranasal administrationofoxy-
tocin, we examined the behavioral and neural effects of the
neuropeptide on the 3 impaired outcomes, ie, the number of
NVJs, the response time for NVJs, and the medial prefrontal
activity during NVJs.
Methods
Participants
Forty highly functioning men with ASD participated in this
study (Figure2) becauseof their firmdiagnosis, age (≥20years),
sex (male), full-scale IQ (>80), andwrittenconsent.The40par-
ticipantswithASD includedall 15 participantswithASD inour
previous case-control fMRI study.8 Seven of them were ex-
cluded because of technical problems (2 participants), cur-
rent use of a psychotropic medication (2 participants), or fre-
quent atypical responses to congruent stimuli (3 participants).
Participants showing frequent atypical responses were de-
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fined as thosewho judged congruent stimuli in counterintui-
tivedirections inmore thanhalf of the trials (ie, friendand foe
judgmentsofNV−V−andNV+V+, respectively) (Figure 2). Con-
sequently, we analyzed fMRI data collected from the remain-
ing 33 nonmedicated participants (mean [SD] age, 28.5 [5.9]
years) (eTable 1 in Supplement). Written informed consent
was obtained from all the participants. The study was con-
ducted in accordancewith theprinciples of theDeclarationof
Helsinki and was approved by the institutional review board
of the University of Tokyo Hospital.
Diagnosis
Experiencedpsychiatrists (H.Y. andN.K.) carefully diagnosed
the participants as having ASD on the basis of the strict crite-
ria of DSM-IV-TR2 after more than 2 months of follow-up ex-
aminations.Diagnoseswere validatedby 1psychiatrist or psy-
Figure 1. Task Design and Effects on Behavior
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A, Participants were instructed to make friend or foe judgments for each movie
in a series of short movies in which a professional actor spoke an emotionally
positive or negative word (verbal information) while exhibiting emotionally
positive or negative facial and vocal expressions (nonverbal information).
B, Responses to incongruent stimuli were classified as nonverbal information–
based judgments (NVJs) or verbal information–based judgments (VJs). NV−V+
indicates stimuli with negative nonverbal information and positive verbal infor-
mation; NV+V−, stimuli with positive nonverbal information and negative verbal
information. C, Intranasal administration of oxytocin significantly increased the
number of NVJs, which was lower in untreated individuals with autism spec-
trum disorders compared with typically developing individuals in our previous
study.8 Error bars indicate standard error of the mean.
D, This oxytocin-induced increase in the number of NVJs was observed regard-
less of the order of drug administration. E, Intranasal oxytocin significantly
decreased response times for the NVJs, which were longer in untreated indi-
viduals with autism spectrum disorders than in typically developing individuals
(eFigure 2 in Supplement). F, This oxytocin-induced shortening of response
times for NVJs was observed regardless of the order of drug administration.
G, The oxytocin-induced increase in the number of NVJs significantly correlated
with oxytocin-induced shortening of response times to incongruent stimuli,
which suggests a common neural effect of oxytocin.
aP < .05.
bP > .05.
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chologist (H.K. or Miho Kuroda, PhD) who confirmed the
diagnoses based on the Japanese version of the Autism Diag-
nostic Interview–Revised32 and/or the AutismDiagnostic Ob-
servation Schedule.33 All participantswith ASD exhibited IQs
ranging from average to above average in the full scale of the
WechslerAdult IntelligenceScale–Revised, Japaneseversion34
(eAppendix 1 in Supplement).
Randomization andMasking of Drug Administration
The randomization and masking manager randomly as-
signedparticipants to initially administeredoxytocin or apla-
cebo group. The manager completely covered the label of
sprays for blinding from the participants and the other re-
search members (eAppendix 1 in Supplement).
Interventions
TheparticipantswithASD intranasally35 receiveda singledose
of oxytocin (24 IU; Syntocinon Nasal Spray)14,30,36 or placebo
at a 1-week interval in a pseudorandom order 40minutes be-
fore the scanning. To avoid any subjective effects of the sub-
stances other than those causedbyoxytocin, theplacebo con-
tainedall inactive ingredients.14Noadverseeffectsofoxytocin
were observed in this study (eAppendix 1 in Supplement).
Task and Stimuli
The task and stimuli in this studywere the sameas thoseused
in our previous case-control8 and healthy participant37 stud-
ies. The stimuli consisted of 80 originalmonochromemovies
with a length of 1.5 seconds (Video). After sufficient training
usingdifferentmovie stimuli, theparticipants underwent the
friendor foe judgment taskusing the80 stimuli (Figure 1A; for
details of the task paradigm, see eAppendix 1 in Supple-
ment).
MRI Scanning
A 3-TMRI scanner (GE Healthcare) at the University of Tokyo
Hospital was used. Axial T2-weighted images were recorded
for the anatomical coregistration. Gradient-echo echo-planar
sequenceswere used for functional imaging (repetition time,
3 seconds; echo time, 35milliseconds; flip angle, 80°;matrix,
4 × 4 × 4 mm3; 22 slices; ventral to dorsal interleaved acqui-
sition). The first 5 functional images in each run were dis-
carded to allow for equilibrium of longitudinal magnetiza-
tion (eAppendix 1 in Supplement).
Statistical Analysis
Behavioral Analysis
After classifying the participants’ responses to the incongru-
ent stimuli intoNVJs andVJs (Figure 1B),we examined the ef-
fects of oxytocin on the number of NVJs by conducting a re-
peated-measures 3-way analysis of variance (ANOVA) of the
numberof judgments for the incongruent stimuli (typeofdrug
[oxytocin or placebo] × typeof response [friendor foe] × type
of stimuli [NV−V+ or NV+V−]). Using a 3-way ANOVAwith the
same structure, we also examined the effects of oxytocin on
response times to incongruent stimuli. Response timewas cal-
culated as time spent fromthe start of eachmovie to eachbut-
tonpress (ie, eachresponse time includes timeforviewingeach
1.5-secondmovie) (eAppendix 1 in Supplement).
fMRI Analysis
ThefMRIdatawereanalyzedusingSPM8software (http://www
.fil.ion.ucl.ac.uk/spm/). The data were preprocessed through
realignment, correction of slice timing, normalization to the
default template with interpolation to a 2 × 2 × 2-mm space
(eAppendix 1 in Supplement),38 and spatial smoothing (full-
width half-maximum, 8 mm; Gaussian filter), and high-pass
temporal filtering (128seconds).Forourevent-related fMRIde-
sign at the single-participant level, we used a general linear
model with regressors for the 4 types of stimuli × the 2 types
of responses. Using these single participant–level data, we
evaluated oxytocin’s NVJ-specific effects on brain activity by
estimating the effects of the interaction in a repeated-
measures 3-way ANOVA of brain activity (type of drug × type
of response × typeof stimuli). This analysiswas conducted as
a region-of-interest (ROI) analysis for 7 brain regions (eTable
2 in Supplement) thatwere apriori selectedon thebasis of our
previous case-control study.8TheROIsweredefinedas4-mm-
radius spheres. To validate the spatial specificity of oxyto-
cin’s neural effects, we also conducted a whole-brain analy-
sis using a random-effects model (P < .05 corrected based on
the family-wise error [FWE] rate). By comparing brain activ-
Figure 2. Enrollment and Randomization of Participants
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Among the 40 individuals with autism spectrum disorders enrolled in this trial,
7 were excluded from the analysis because of technical problems in recording
behavioral data (2 participants), current use of psychotropic medications (2
participants), or frequent unnatural responses to the congruent stimuli (3
participants). As their unnatural responses, 1 of the 3 excluded participants
judged actors with positive nonverbal and positive verbal information as foe in
19 of 20 stimuli in the oxytocin session and 11 of 20 stimuli in the placebo
session, 1 participant judged actors with positive nonverbal and positive verbal
information as foe in 20 of 20 stimuli in both the oxytocin and placebo sessions,
and the other judged actors with negative nonverbal and negative verbal
information as friend in 11 of 20 stimuli in both the oxytocin and placebo
sessions. In the remaining 33 participants, the number of atypical responses
ranged from0 to 4. We observed essentially the same statistical
conclusions when the 2medicated participants were not excluded
(eAppendix 2 in Supplement).
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ity between NVJs and VJs, we reduced the effects of cog-
nitive components related to general judgments on brain
activity.
Because we found significant effects of oxytocin only on
the2medialprefrontalROIs (theanteriorcingulatecortex[ACC]
and dorsal medial prefrontal cortex [dmPFC]) among the 7
ROIs,wethenestimatedfunctional connectivitybetweenthem
by calculating the psychophysiological interaction (PPI)39,40
using themethod implemented inSPM8.ThePPIanalyseswere
first conducted between the ACC and dmPFC. To confirm the
spatial specificity of theROI-basedPPI analyses,we then con-
ducted voxelwise whole-brain PPI analyses with the dmPFC
as a seed (eAppendix 1 in Supplement).
As a control,we also evaluated oxytocin’s effects onbrain
activity during congruent stimuli trials at awhole-brain level.
Results
Oxytocin Increases the Number of NVJs
A repeated-measures 3-way ANOVA on the number of judg-
ments of the incongruent stimuli detected a significant 3-way
interaction (F1,32 = 5.1,P = .03) (eTable4 inSupplement).Apost
hoc paired t test showed that the number of NVJs was signifi-
cantly greaterduring theoxytocin session thanduring thepla-
cebo session in the individuals with ASD (t32 = 2.2, P = .03,
Cohend = 0.55) (Figure 1C).This effectwas independentof the
order in which drugs were administered (Figure 1D) because
in a mixed-design repeated-measures 2-way ANOVA on the
number of NVJs (the order of drug × the type of drug), we did
not detect a significant main effect of the order of drug ad-
ministrationor any significant interaction (P = .74andP = .86,
respectively)butdetectedasignificantmaineffectofdrug type
(F1,32 = 4.9,P = .03).These findings suggest that intranasaloxy-
tocin significantly increases the number of NVJs, which was
originally below the levels of TD individuals.8
Oxytocin Shortens Response Times in the Processing
of Incongruent Stimuli
A repeated-measures 3-wayANOVAon the response times for
the incongruent stimuli detected a significant 3-way interac-
tion (F1,32 = 5.9, P = .02). A post hoc paired t test revealed that
oxytocin administration significantly shortened the re-
sponse times for NVJs as compared with placebo administra-
tion(t32 = 2.5,P = .02,d = 0.63) (Figure1E).Conductingamixed-
designrepeated-measures2-wayANOVAontheresponse times
for NVJs (the order of drug × the type of drug), we confirmed
that this behavioral effect was independent of the order in
which drugswere administered (no significantmain effect of
the order of drug administration [P = .67] or any type of sig-
nificant interaction [P = .71]; significant main effect of types
of drug [F1,32 = 4.8, P = .04]) (Figure 1F). In addition, oxyto-
cin’s effect on response time was independent of that on the
number of NVJs, as oxytocin’s shortening effect on response
time was present even when we compared response time for
stimuli to which the participants showed the same judg-
ments inbothoxytocinandplacebosessions (t32 = 2.2,P = .04)
(eFigure 4 in Supplement).
Together, these behavioral results suggest that intranasal
oxytocin enables individuals with ASD to process verbal and
nonverbal incongruent social information inamore typical and
smoother manner. Furthermore, the magnitudes of the 2 be-
havioral effectsweresignificantlycorrelated (r = −0.43,P = .01)
(Figure 1G), which suggests the existence of common neural
mechanisms by which oxytocin affects these behavioral
processes.
Oxytocin Recovers ImpairedMedial Prefrontal Activity
We next investigated the neural mechanisms underlying the
behavioral effects of oxytocin. A repeated-measures 3-way
ANOVA on brain activity of the 7 ROIs (eTable 2 in Supple-
ment) revealed significant 3-way interactions in the ACC and
dmPFC(F1,32 > 15.5,P < .05,Bonferronicorrected for the7ROIs;
neithermaineffectsnor2-wayinteractions,P > .40) (Figure3A).
A post hoc paired t test showed that oxytocin significantly in-
creased NVJ-specific brain activity (NVJs minus VJs) in these
2 medial prefrontal cortex regions (mPFCs) (ACC: t32 = 4.1,
P < .001, d = 1.1; dmPFC: t32 = 3.9, P < .001, d = 1.1).
The spatial specificity of our ROI analysis was con-
firmed by a stricter voxelwise whole-brain search, which
found that the 2 mPFCs showed significant oxytocin-
induced increases in NVJ-specific brain activity (ie,
[NVJs > VJs]oxytocin > [NVJs > VJs]placebo; t32 > 5.1, PFWE < .05,
d > 1.5) (Figure 3B). Although other brain regions also
showed significant increases in activity (eFigure 6 in
Supplement; Table), the locations of the medial prefrontal
activations in this whole-brain analysis were close to and
partially overlapped with those of our predefined ACC and
dmPFC ROIs (Figure 3B), suggesting that oxytocin does not
increase overall brain activity but specifically recovers the
originally diminished activities of the ACC and dmPFC.
OxytocinMakesMedial Prefrontal Activity Patterns
of ASD Resemble Those of TD
We found that intranasal oxytocin not only restores activity
but alsomakes the activity patterns in themPFCsmore simi-
lar to those we observed in TD individuals in our previous
study.8 First, only in theoxytocin session, brain activity in the
ACCanddmPFCwas significantlygreaterduringNVJs thanVJs
(ACC: t32 = 3.6,P < .001;dmPFC: t32 = 5.8,P < .001) (Figure3A).
Inourprevious study,8 this activitypatternwasobservedonly
inTD individuals but not in individualswithASDwithout any
drug administration.
Moreover, we found another similarity in the relation-
shipbetweenbehavioral andneural responsesbetweenTD in-
dividuals and individualswithASDwho receivedoxytocin. In
our previous case-control study,8 we observed significantly
positive correlations across participants between thenumber
ofNVJs andNVJ-specific brain activity in theACCanddmPFC
in TD individuals but not in individuals with ASD. Here, we
found significantpositive correlationsbetween thenumberof
NVJs and NVJ-specific brain activity in both the ACC and
dmPFC only after oxytocin administration (ACC: r = 0.69,
P < .001; dmPFC: r = 0.66, P < .001; P < .05 Bonferroni cor-
rected for the 7ROIs) (Figure 3C). Thedifferences between the
correlation coefficients under oxytocin and placebo sessions
Oxytocin and Autism Sociocommunicational Deficits Original Investigation Research
jamapsychiatry.com JAMAPsychiatry Published online December 18, 2013 E5
Downloaded From: http://archpsyc.jamanetwork.com/ by a University College London User  on 12/18/2013
Copyright 2013 American Medical Association. All rights reserved.
were statistically significant in both regions (ACC: Z = 2.9,
P = .002; dmPFC: Z = 2.7,P = .003). These results suggest that
oxytocin enabled the participants with ASD to recruit their
ACCsanddmPFCs forprocessingof social communicationcon-
tent in a manner that is similar to TD individuals.
Oxytocin’s Neural Effects Are Predictive
of Its Behavioral Effects
Furthermore, we examined whether our observed neural ef-
fectsare thebasis for theobservedbehavioral effectsandfound
significant correlations between oxytocin-engendered in-
Figure 3. Effects on Brain Activity
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A, Oxytocin significantly increased nonverbal information–based judgment
(NVJ)–specific activity (NVJ > verbal information–based judgment [VJ]) only in
the anterior cingulate cortex (ACC) and dorsal medial prefrontal cortex
(dmPFC), whose activity was lower in untreated individuals with autism
spectrum disorders (ASD) than in typically developing (TD) individuals in our
previous study.8 Even in the oxytocin session alone, activity in the ACC and
dmPFCwas significantly greater during NVJs than VJs, which had previously
been observed only in TD individuals and not in individuals with ASD.8 To show
the interaction of brain activity (type of drug × type of response × type of
incongruent stimuli), we previously calculated the interaction between the
latter 2 factors as the difference between NVJ and VJ. AI indicates anterior
insula; IFG: inferior prefrontal gyrus; Lt, left; Rt, right; STP: superior temporal
pole; and error bars, standard error of themean. B, A voxelwise whole-brain
search found significant activations in themedial prefrontal cortex (Table;
eFigure 6 in Supplement), an area related to various introspective and social
cognitions. Its location partially overlapped with our predefined ACC and
dmPFC regions of interest (circles), which supports the regional specificity of
oxytocin’s neural effects. P < .001, uncorrected for presentation purposes. C,
The NVJ-specific activity in the ACC and dmPFC showed significant positive
correlations with the number of NVJs only after oxytocin administration. In our
previous case-control study,8 these correlations were also observed in TD
individuals but not in ASD individuals. Oxytocin-induced increases in
NVJ-specific brain activity in the ACC and dmPFCwere significantly correlated
with oxytocin-induced increases in the number of NVJs (D) and
oxytocin-induced shortening of response times for NVJs (E).
aP < .05, Bonferroni corrected.
bP < .001.
cP < .05.
dP < .01.
eP < .01 in a test of the differences between 2 Pearson correlation coefficients.
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creases in the number of NVJs and the increases in NVJ-
specific brain activity in both the ACC and dmPFC across par-
ticipants (ACC: r = 0.77, P < .001; dmPFC: r = 0.71, P < .001;
P < .05Bonferroni corrected for the 2 regions) (Figure 3D).We
also detected significant correlations between oxytocin-
engendered decreases in response times for NVJs and in-
creases in NVJ-specific activity in both the ACC and dmPFC
(ACC: r = −0.44, P = .01; dmPFC: r = −0.52, P = .001; P < .05
Bonferroni corrected for the 2 regions) (Figure 3E).
Oxytocin Enhances Functional Coordination AmongmPFCs
Thesefindings implythatcoordinatedactivitybetweentheACC
anddmPFCmediates the beneficial effects of oxytocin on be-
havioral difficulties in individuals with ASD. Indeed, func-
tional connectivity analyses revealed that oxytocin
significantly increased theNVJ-specific connectivity fromthe
dmPFCto theACC (t32 = 4.4,P < .001,paired t test) (Figure4A).
The spatial specificity of this effect was confirmed by a vox-
elwisewhole-brainconnectivityanalysis,whichdetectedasig-
Figure 4. Effects of Oxytocin on Functional Connectivity
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A, Intranasal oxytocin significantly enhanced nonverbal information–based
judgment (NVJ)–specific functional connectivity (psychophysiological
interaction) from the dorsal medial prefrontal cortex (dmPFC) to the anterior
cingulate cortex (ACC), whereas it did not enhance the opposite connectivity.
Significance is shown for greater functional connectivity during NVJs than
verbal information–based judgments (VJs) in the oxytocin session alone. Error
bars indicate standard error of themean. B, Our predefined ACC region of
interest partially overlapped with the region that showed increased
connectivity from the dmPFC in a voxelwise whole-brain connectivity analysis
with the dmPFC seed (eTable 5 in Supplement). This result reveals the spatial
specificity of oxytocin-induced enhancements of functional connectivity from
the dmPFC. P < .001, uncorrected for presentation purposes. C, The
NVJ-specific connectivity from the dmPFC to the ACC significantly correlated
with the number of NVJs only after oxytocin administration, which suggests
that this connectivity is associated with NVJs. Oxytocin-induced enhancement
of functional connectivity from the dmPFC to the ACC significantly correlated
with oxytocin-induced increases in the number of NVJs (D) and shortening of
response times for NVJs (E).
aP < .001.
bP > .05.
cP < .01 in 1-sample t test.
dP < .05.
Table. Results of a VoxelwiseWhole-Brain Analysisa
Right or Left Anatomical Label
MNI Coordinate
Cluster Size, No. of Voxels t Valuex y z
Right ACC 0 36 4 316 5.1
Right dmPFC 2 26 48 412 5.5
Left SFG −34 50 −2 348 5.9
Left STS −58 −16 4 582 5.3
Abbreviations: ACC, anterior cingulate cortex; dmPFC, dorsal medial prefrontal
cortex; MNI, Montreal Neurological Institute; SFG, superior frontal gyrus; STS,
superior temporal sulcus.
a (Nonverbal information–based judgment > verbal information–based
judgment)oxytocin > (nonverbal information–based judgment > verbal
information–based judgment)placebo; P < .05, family-wise error corrected.
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nificant oxytocin-induced increase in connectivity from the
dmPFC to a medial prefrontal region that was near our pre-
defined ACC ROI (t32 = 4.8, PFWE < .05) (Figure 4B; eFigure 7
and eTable 5 in Supplement). Moreover, themagnitude of this
NVJ-specific functional connectivity exhibited a significantly
positive correlation with the number of NVJs only after oxyto-
cin administration (r = 0.39,P = .02) (Figure4C); thedifference
in the correlations between the oxytocin and placebo sessions
was statistically significant (Z = 1.8, P = .03). Furthermore, the
oxytocin-induced enhancement of functional connectivity
from the dmPFC to the ACC was significantly positively corre-
lated with both oxytocin-induced increases in the number of
NVJs (r = 0.54, P = .001) (Figure 4D) and oxytocin-induced
shortening of NVJ response times (r = −0.41, P = .01)
(Figure 4E). These results suggest that oxytocin might miti-
gate the sociocommunicational deficits of ASD through the
coordinated enhancement of activity in the dmPFC and ACC.
Oxytocin’s Effects on Amygdalar Activity
in Congruent Control Stimuli Trials
As a control, we examined oxytocin’s suppressive effect on
amygdalar responses to emotional stimuli,whichhasbeen re-
ported in a series of previous studies.15,17,26,36,41-45 A repeated-
measures 2-wayANOVAof amygdalar activity during congru-
ent stimuli trials (type of drug [oxytocin or placebo] × type of
congruent stimuli)detectedasignificantdecrease in theamyg-
dala, whose location was predefined based on our previous
case-control study8 (F1,32 = 13.5,P < .001; no other significant
main effect or interaction) (eFigure 9A in Supplement). A vox-
elwisewhole-brain analysis confirmed theeffect on theamyg-
dala aswell as on other brain regions (PFWE < .05) (eFigure 9B
and eFigure 10 in Supplement).
Additional results such as oxytocin’s effects on eye gaze
(eFigure 3 in Supplement), relationship of oxytocin-induced
shorteningofresponsetimestosocialresponsivenessscale(eFig-
ure 5 in Supplement), functional connectivity from the ACC to
the dmPFC (eFigure 8 in Supplement), robustness of results to
participant selection (eFigure 11 in Supplement), and behavior
to control stimuli (eTable 3 in Supplement) are also reported.
Discussion
This study demonstrates that intranasal administration of
oxytocin enables highly functioning individuals with ASD to
exhibit more typical and smoother behavioral responses to
social communication for which verbal and nonverbal infor-
mation is conflicting. Moreover, we showed that the behav-
ioral effects of oxytocin could be explained by oxytocin-
induced restoration of deficits in brain activity in the ACC
and dmPFC and oxytocin-induced enhancement of func-
tional connectivity from the dmPFC to the ACC. These find-
ings elucidate the neural mechanisms underlying oxytocin’s
beneficial effects for sociocommunicational deficits in ASD,
and they provide, to our knowledge, the initial evidence
regarding the neurobiological basis for any useful effect of
oxytocin for the core symptoms of ASD. Furthermore, our
results suggest that medial prefrontal activity during pro-
cessing of incongruent verbal and nonverbal stimuli may be
a promising neural biomarker for the evaluation of benefi-
cial effects on sociocommunicational deficits in highly
functioning individuals with ASD.
It is not clear whether the administration of oxytocin can
fully recover the sociocommunicationaldeficits inhighly func-
tioning individualswithASD. Indeed, in this study, themainbe-
havioralandneurologicaloutcomesof individualswithASDwho
receivedoxytocinwerenotsignificantlydifferent fromthoseob-
served in TD individuals in our previous study (P > .30) (eAp-
pendix 2 in Supplement). However, we cannot assume thera-
peutic effects of oxytocin based on these results. This study
examined only some of the sociocommunicational deficits in
ASDanddidnot investigatewhether thesebeneficialeffectscan
be maintained after long-term administration. To validate the
effects found in this study, future studiesneed toexamineboth
the effects of oxytocin on other aspects of sociocommunica-
tional deficits and its effects after long-term administration.
In addition, caution should be used concerning oxyto-
cin’spotential adverseeffects in future long-termclinical trials.
Someprevious studieswithTDparticipants reported that oxy-
tocin increased defensive responses to negative emotional
stimuli46 and induced avoidance of positive stimuli in a cer-
tain condition.47 These studies imply that repeated adminis-
trationof oxytocinmight inducehighly functioning individu-
als with ASD to hold overdefensive attitudes to emotionally
negative information. Future long-termadministrationof the
neuropeptidewill need to take intoaccount thesepotential ad-
verse effects.
The 33 participants examined in this study include all 15
highly functioning individuals with ASD who participated in
our previous case-control study.8 Although this overlap of
participants might increase the possibility of false-positives
in the present findings, at the very least, the effects on the
ACC and dmPFC are likely free from this potential error.
Similar decreases of activity in a region close to the dmPFC
have been reported in other previous studies that examined
brain activity in individuals with ASD during the compre-
hension of irony.20,29 Based on the correspondence between
the results of this study and previous studies, it is reason-
able to interpret our findings as evidence that intranasal
oxytocin recovers deficits in brain activity in highly func-
tioning individuals with ASD that are linked to the clinical
severity of their sociocommunicational impairments.
Our results regarding the sensitivity of the mPFCs to
exogenous oxytocin are consistent with previous studies
showing the existence of a large number of oxytocin recep-
tors in the mPFC of prairie voles48,49 and the associations
between oxytocin receptor alleles and functions and struc-
tures in the human mPFC.19,50-52 In addition, previous fMRI
studies of TD participants have suggested that oxytocin’s
functional effects are observed particularly in regional activ-
ity and functional connectivity among the brain regions
related to social cognition.23 Considering these microscopic
and mesoscopic findings, changes in activity and connectiv-
ity related to the mPFC may be an endophenotype that links
oxytocin’s behavioral effects with its influences on cellular
and molecular systems.
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Conclusions
Our findings provide both behavioral and neural evidence
for oxytocin’s therapeutic effects on sociocommunicational
deficits of ASD. The study also suggests an important role of
mPFC activity as an endophenotype linking oxytocin’s
behavioral effects with its influences on cellular and
molecular systems, which is translatable into future animal
models.
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